The Prostate Cancer Center at Lenox Hill Hospital in New York has found that MRI-guided biopsy is a more effective method for detecting and diagnosing high risk and aggressive prostate cancers. According to David B. Samadi, MD, he and his team at Lenox are using the UroNav MR/Ultrasound Fusion Biopsy System from Invivo Corporation for guidance of targeted prostate biopsy for cancer screening. UroNav is said to fuse pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time.

“MRI-guided fusion biopsy could be a game-changer in the field of urology and prostate cancer,” said Samadi, noting that the fusion of MR/ultrasound and standard biopsy is more targeted, which results in fewer false negatives. “The technology is not 100%, but this formulation of testing may be the magic mix we need to fully understand and effectively diagnose aggressive prostate cancer.”

Samadi reports that the main advantage of using MRI-guided biopsy to detect and diagnose prostate cancer is the ability to view the entire gland. Additionally, the system’s small footprint is intended to make it possible to perform exams in offices.

For more information about the UroNav MR/Ultrasound Fusion Biopsy System used at Lenox Hill Hospital, visit the Invivo website.